Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade.

Ishibashi K, Haber T, Breuksch I, Gebhard S, Sugino T, Kubo H, Hata J, Koguchi T, Yabe M, Kataoka M, Ogawa S, Hiraki H, Yanagida T, Haga N, Thüroff JW, Prawitt D, Brenner W, Kojima Y.

Oncotarget. 2017 Jul 21;8(33):55230-55245. doi: 10.18632/oncotarget.19420. eCollection 2017 Aug 15.

2.

Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.

Park JE, Ryu KH, Kim HS, Kim HW, Shim WH, Jung SC, Choi CG, Kim SJ, Kim JH.

PLoS One. 2017 Jul 21;12(7):e0181933. doi: 10.1371/journal.pone.0181933. eCollection 2017.

3.

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.

Wang X, Solban N, Khanna P, Callea M, Song J, Alsop DC, Pearsall RS, Atkins MB, Mier JW, Signoretti S, Alimzhanov M, Kumar R, Bhasin MK, Bhatt RS.

Oncotarget. 2016 Jul 5;7(27):41857-41869. doi: 10.18632/oncotarget.9621.

4.

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.

Chen J, Ji T, Zhao J, Li G, Zhang J, Jin R, Liu J, Liu X, Liang X, Huang D, Xie A, Lin H, Cang Y, Cai X.

Oncotarget. 2016 Jul 5;7(27):41274-41284. doi: 10.18632/oncotarget.8978.

5.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS.

Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Erratum in: Lancet. 2016 May 14;387(10032):1998.

6.

Volumetric Arterial Spin-labeled Perfusion Imaging of the Kidneys with a Three-dimensional Fast Spin Echo Acquisition.

Robson PM, Madhuranthakam AJ, Smith MP, Sun MR, Dai W, Rofsky NM, Pedrosa I, Alsop DC.

Acad Radiol. 2016 Feb;23(2):144-54. doi: 10.1016/j.acra.2015.09.013. Epub 2015 Oct 29.

7.

Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments.

Zhang Y, Kapur P, Yuan Q, Xi Y, Carvo I, Signoretti S, Dimitrov I, Cadeddu JA, Margulis V, Muradyan N, Brugarolas J, Madhuranthakam AJ, Pedrosa I.

Clin Genitourin Cancer. 2016 Feb;14(1):e25-36. doi: 10.1016/j.clgc.2015.08.007. Epub 2015 Aug 29.

8.

Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.

Jeon TY, Kim CK, Kim JH, Im GH, Park BK, Lee JH.

Br J Radiol. 2015 Sep;88(1053):20150163. doi: 10.1259/bjr.20150163. Epub 2015 Jul 2.

9.

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.

Shibasaki N, Yamasaki T, Kanno T, Arakaki R, Sakamoto H, Utsunomiya N, Inoue T, Tsuruyama T, Nakamura E, Ogawa O, Kamba T.

PLoS One. 2015 Jun 26;10(6):e0130980. doi: 10.1371/journal.pone.0130980. eCollection 2015.

10.

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS.

Clin Cancer Res. 2015 Apr 15;21(8):1925-1934. doi: 10.1158/1078-0432.CCR-14-2031. Epub 2015 Jan 14.

11.

Hepatic arterial spin labelling MRI: an initial evaluation in mice.

Ramasawmy R, Campbell-Washburn AE, Wells JA, Johnson SP, Pedley RB, Walker-Samuel S, Lythgoe MF.

NMR Biomed. 2015 Feb;28(2):272-80. doi: 10.1002/nbm.3251. Epub 2014 Dec 17.

12.

The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.

Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS.

Transl Oncol. 2014 Apr;7(2):188-95. doi: 10.1016/j.tranon.2014.02.003. Epub 2014 Mar 4.

13.

MRI phenotype in renal cancer: is it clinically relevant?

Campbell N, Rosenkrantz AB, Pedrosa I.

Top Magn Reson Imaging. 2014 Apr;23(2):95-115. doi: 10.1097/RMR.0000000000000019. Review.

14.

Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI.

Rajendran R, Huang W, Tang AM, Liang JM, Choo S, Reese T, Hentze H, van Boxtel S, Cliffe A, Rogers K, Henry B, Chuang KH.

Cancer Med. 2014 Feb;3(1):47-60. doi: 10.1002/cam4.177. Epub 2014 Jan 6.

15.
16.

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.

Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS.

Br J Cancer. 2013 Feb 5;108(2):319-26. doi: 10.1038/bjc.2012.591. Epub 2013 Jan 15.

17.

Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.

Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, Genega EM, Rofsky NM, Alsop DC, Pedrosa I.

Radiology. 2012 Dec;265(3):799-808. doi: 10.1148/radiol.12112260. Epub 2012 Oct 9.

18.

Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.

Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, Takiguchi M, Tamaki N, Kuge Y.

Int J Oncol. 2012 Nov;41(5):1593-600. doi: 10.3892/ijo.2012.1624. Epub 2012 Sep 10.

19.

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS.

J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220.

20.

Supplemental Content

Support Center